Ocugen Draws Institutional Heavyweights Even as Share Price Stumbles Ahead of Key Data

Ocugen shares fall 7.8% despite institutional buying; Phase 1/2 data for OCU410 and OCU410ST due Sept 23-24.

The disconnect between Ocugen's clinical momentum and its market valuation has rarely been starker. While the gene therapy developer prepares to unveil fresh trial results before the Retina Society later this month, some of Wall Street's most prominent investment houses have been quietly accumulating stock — even as retail sentiment pushes the shares lower.

BlackRock has emerged as a particularly notable buyer. A regulatory filing shows the asset manager now controls 27,002,933 Ocugen shares, equivalent to a 7.96% stake in the company. The accumulation extends well beyond the world's largest money manager, with Goldman Sachs, UBS, State Street, and Hennion & Walsh all expanding their holdings in recent weeks. Institutional investors collectively now own 10.27% of the outstanding shares — a figure that suggests professional money managers are increasingly willing to underwrite the company's long-term prospects despite the near-term turbulence.

That institutional conviction stands in sharp contrast to Tuesday's trading action. The stock slipped 7.8% to €1.15 in German markets, widening the gap from its 52-week high to 51%. The pullback follows Monday's session, when shares closed up 6.3% at €1.25. The recent recovery had briefly pushed the equity roughly 5.2% above its 50-day moving average, though the distance from the yearly peak remains substantial at 47%.

A September Calendar Packed With Catalysts

The market's attention now shifts to a dense schedule of investor and scientific engagements. Management kicks things off Wednesday with a CEO fireside chat at the Citi 2026 Biopharma Back to School Conference, followed by an appearance at H.C. Wainwright's event on September 15. The centerpiece, however, arrives on September 23 and 24, when the company presents before the Retina Society.

Those presentations will carry considerable weight. Ocugen plans to release safety and tolerability data from the Phase 1 trial of OCU410ST in Stargardt disease, alongside results from the Phase 2 ArMaDa study evaluating OCU410 in geographic atrophy, an advanced form of dry age-related macular degeneration. The data dump is widely viewed as a pivotal input for the strategic direction of the company's clinical pipeline.

Regulatory Milestones Already in the Rearview

The groundwork for OCU410's long-term trajectory is already being laid. Just over a week ago, Ocugen dosed the first patient in ArMaDa3, the global Phase 3 registrational trial for the candidate. The program received a significant regulatory boost on July 29, when the FDA granted Regenerative Medicine Advanced Therapy (RMAT) status — a designation reserved for therapies addressing serious conditions that can accelerate the approval pathway. The company currently targets a Biologics License Application submission in 2028, with parallel discussions underway with the European Medicines Agency to prepare the ground for potential European market entry.

Whether the upcoming scientific presentations can bridge the gap between institutional optimism and the share price's recent slide remains an open question. The conference circuit offers management a platform to detail patient dosing progress and platform advancements — but with the 52-week high still a distant memory, the market appears to be demanding more than promises.